



January 22, 2020
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

Announcement of Joint Research Agreement for Cerebral Palsy with 3 Institutes

Tokyo, January 22, 2020 – Gene Techno Science Co., Ltd. (“GTS”) executed a joint research agreement with Tokyo Metropolitan Institute of Medical Science, Nagoya University Hospital, and Tokyo Medical and Dental University for research and development of new therapeutic treatments for cerebral palsy.

1. Purpose and background for concluding this agreement

Cerebral palsy is a cerebral dysfunction that occurs at a frequency of 1 in 500 births due to the cerebral blood flow reduction and/or infection during the perinatal period. As the current treatment is limited in applicable cases and its efficacy, the development of new treatments is awaited, and cell therapy is considered as one of the candidates. Stem cells from human exfoliated deciduous teeth (“SHED”) have excellent capabilities of nerve regeneration and anti-inflammation, proposing the potential to suppress loss of functions and/or promote gain of functions in cerebral palsy.

The Tokyo Metropolitan Institute of Medical Science has set up a research theme called "Children's brain development" and is conducting basic research aimed at treating children with brain diseases. In addition, Nagoya University Hospital and Tokyo Medical and Dental University execute cutting-edge regenerative medicine research for various diseases, and have a wealth of research experiences in cell therapy for cerebral palsy. With regard to the potential new therapy utilizing SHED owned by GTS, we believe to achieve synergistic research outcome by complementing the research bases, knowledge, and scientists in four parties, resulting in this joint research agreement. We will swiftly proceed with this joint research to provide a new therapeutic option to the children with cerebral palsy and their families as soon as possible.

2. Outline of counterparties to this agreement

1. Name	Gene Techno Science Co., Ltd.
2. Location	1-2-12, Shinkawa, Chuo-ku, Tokyo
3. President and CEO	Masaharu Tani

1. Name	Tokyo Metropolitan Institute of Medical Science
2. Location	2-1-6 Kamikitazawa, Setagaya-ku, Tokyo
3. Chairperson	Keiji Tanaka
4. Department	Department of Brain Development and Neural Regeneration

1. Name	Nagoya University Hospital
2. Location	65 Tsurumai-cho, Showa-ku, Nagoya
3. Hospital Director	Yasuhiro Kodera
4. Department	Division of Neonatology, Center for Maternal-Neonatal Care

1. Name	Tokyo Medical and Dental University
2. Location	1-5-45 Yushima, Bunkyo-ku, Tokyo
3. President	Yasuyuki Yoshizawa
4. Department	Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences

3. Future outlook

The impact on the business results for the fiscal year ending March 2020 is expected to be minimal.

About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and

provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

Contact:

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547 Mail: info@g-gts.com